Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Neovascular Age-related Macular Degeneration (AMD)”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Study completedNCT03927690
What this trial is testing

Multiple Dose Safety and Efficacy of LKA651 in Patients With Diabetic Macular Edema

Who this might be right for
Diabetic Macular Edema
Novartis Pharmaceuticals 91
Post-approval studies (Phase 4)Study completedNCT02441816
What this trial is testing

VITAL - Individualising Therapy for Neovascular AMD With Aflibercept

Who this might be right for
Age Related Macular Degeneration
Moorfields Eye Hospital NHS Foundation Trust 50
Large-scale testing (Phase 3)UnknownNCT05539235
What this trial is testing

Efficacy and Safety of Intravitreal Conbercept With Modified Treat-and-Extend Regimens in Exudative AMD

Who this might be right for
Exudative Age-Related Macular Degeneration
First Affiliated Hospital of Chongqing Medical University 60
Not applicableStudy completedNCT07105228
What this trial is testing

Incidence of Retinal Vasculitis Among Patients Receiving Aflibercept: A US Real-World Evidence Study

Who this might be right for
Retinal Vasculitis
Regeneron Pharmaceuticals 290,000
Early research (Phase 1)Study completedNCT04422899
What this trial is testing

Effect of Intravitreally Administered AIV007 in Subjects With Neovascular Age-Related Macular Degeneration

Who this might be right for
Neovascular Age-related Macular Degeneration
AiViva BioPharma, Inc. 3
Testing effectiveness (Phase 2)UnknownNCT06183814
What this trial is testing

EXG102-031 in Participants With wAMD

Who this might be right for
Neovascular Age-related Macular Degeneration
Guangzhou Jiayin Biotech Ltd 42
Not applicableStudy completedNCT01291121
What this trial is testing

Intravitreal Ranibizumab in Exudative Age-related Macular Degeneration With Posterior Vitreomacular Adhesion

Who this might be right for
Neovascular Age-related Macular Degeneration
Yonsei University 30
Not applicableStudy completedNCT07744984
What this trial is testing

The Efficacy of Home OCT Supported Management in Patients Diagnosed With Neovascular-AMD and Undergoing a Drug Switch to Faricimab

Who this might be right for
Age-Related Macular Degeneration (AMD)Neovascular Age-Related Macular Degeneration (nAMD) Wet AMD
Rabin Medical Center 12
Early research (Phase 1)WithdrawnNCT02450981
What this trial is testing

Evaluation the Pharmacokinetics, Safety, Tolerability of BCD-021 in Patients With Neovascular Age-related Macular Degeneration

Who this might be right for
Neovascular Age-related Macular Degeneration
Biocad
Not applicableLooking for participantsNCT04985487
What this trial is testing

Regulatory Post-Marketing Surveillance Study for Brolucizumab

Who this might be right for
Neovascular Age-related Macular Degeneration
Novartis Pharmaceuticals 3,000
Not applicableUnknownNCT01655589
What this trial is testing

VEGF Gene Association With Response to Neovascular Age-related Macular Degeneration With Anti-VEGF Agents

Who this might be right for
Macular Degeneration
Institute of Vision, Brasil 74
Not applicableStudy completedNCT04723160
What this trial is testing

Computer Aided Diagnosis of Multiple Eye Fundus Diseases From Color Fundus Photograph

Who this might be right for
Diabetic RetinopathyRetinal Vein OcclusionRetinal Artery Occlusion+10 more
Visionary Intelligence Ltd. 748
Not applicableStudy completedNCT00549055
What this trial is testing

A Study On The Efficacy Of Macugen Injections In Patients With Neovascular Age-Related Macular Degeneration In Real Life.

Who this might be right for
Neovascular Age-related Macular Degeneration
Pfizer 38
Large-scale testing (Phase 3)Study completedNCT00090623
What this trial is testing

RhuFab V2 (Ranibizumab) in Subjects With Subfoveal Choroidal Neovascularization Secondary to Age-Related Macular Degeneration (AMD)

Who this might be right for
Macular Degeneration
Genentech, Inc. 180
Testing effectiveness (Phase 2)Study completedNCT00605423
What this trial is testing

The MAP Study: Fluocinolone Acetonide (FA)/Medidur (TM) for Age Related Macular Degeneration (AMD) Pilot

Who this might be right for
Age Related Macular Degeneration
Johns Hopkins University 6
Not applicableStudy completedNCT04642183
What this trial is testing

Single In-Clinic Encounter With the Notal Vision Home OCT

Who this might be right for
Neovascular Age-related Macular DegenerationIntermediate Age Related Macular Degeneration (Disorder)
Notal Vision Inc. 70
Post-approval studies (Phase 4)UnknownNCT03056079
What this trial is testing

Cytokine and Visual Outcome Variations in Eyes Receiving Aflibercept

Who this might be right for
Age Related Macular DegenerationDiabetic Macular EdemaRetinal Vein Occlusion+1 more
Unity Health Toronto 168
Testing effectiveness (Phase 2)Study completedNCT02302989
What this trial is testing

Prophylactic Ranibizumab for Exudative Age-Related Macular Degeneration

Who this might be right for
Age-related Macular Degeneration
Leonard Feiner, MD, PhD 4
Early research (Phase 1)Study completedNCT01154062
What this trial is testing

Evaluate Pazopanib Tablets in Patients Who Have Neovascular Age-related Macular Degeneration

Who this might be right for
Macular Degeneration
GlaxoSmithKline 15
Large-scale testing (Phase 3)Study completedNCT04239027
What this trial is testing

Assess the Effects of Brolucizumab in Adult Patients With Neovascular Age Related Macular Degeneration

Who this might be right for
Neovascular Age Related Macular Degeneration
Novartis Pharmaceuticals 210
Next Page